Clinical Trial Update: Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients [Phase 3]

View source ↗

Summary

Phase 3 trial results update on initiating mealtime ultra-rapid-acting inhaled insulin (Afrezza) in adults with uncontrolled Type 2 diabetes; the study is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)

Snippet

Sponsor: Model Clinical Research LLC | Conditions: Type2 Diabetes | Phase 3 | Status: COMPLETED | Results posted: 2024-06-26